Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.46 |
| ▸ | BRS3 | P32247 | 2/20 | 0.42 |
| ▸ | ATP4A | P20648 | 8/20 | 0.41 |
| ▸ | ATP4B | P51164 | 8/20 | 0.41 |
| ▸ | ATP1A1 | P05023 | 6/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 6/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.41 |
| ▸ | FXYD2 | P54710 | 6/20 | 0.41 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | WDR5 | P61964 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.41 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988452 | 1.00 | SARM1 (0.46) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988397 | 1.00 | SARM1 (0.46) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL9528523 | 0.93 | ATP4A (0.46) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988477 | 0.92 | SARM1 (0.45) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988471 | 0.92 | SARM1 (0.45) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988374 | 0.92 | SARM1 (0.45) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988390 | 0.90 | SARM1 (0.44) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988339 | 0.90 | SARM1 (0.44) | SARM1BRS3ATP4AATP4BATP1A1 | |
| SCHEMBL23988444 | 0.90 | SARM1 (0.44) | SARM1BRS3ATP4AATP4BATP1A1 | |
| Omeprazole SCHEMBL82985 | 0.90 | BRS3 (0.52) | SARM1BRS3ATP4AATP4BATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | SARM1 3076/4885BRS3 4688/4885ATP4A 4581/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | SARM1 3076/4885BRS3 4688/4885ATP4A 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.